Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.73 [0.65, 0.84] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.68 [0.57, 0.81] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
progression or deaths (PFS) | 0.56 [0.50, 0.63] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 3.43 [1.77, 6.66] | | > 1 | | 83% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 2.03 [0.18, 23.06] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 2.44 [1.17, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 4.10 [0.18, 92.93] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 2.58 [1.16, 5.75] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.99 [0.65, 1.49] | | < 1 | | 67% | 5 studies (5/-) | 52.7 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.86 [0.50, 1.48] | | < 1 | | 81% | 5 studies (5/-) | 71.3 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.52 [0.30, 7.54] | | < 1 | | 0% | 5 studies (5/-) | 30.6 % | some concern | serious | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.25 [0.81, 1.94] | | < 1 | | 42% | 5 studies (5/-) | 16.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.92 [0.84, 4.37] | | < 1 | | 0% | 4 studies (4/-) | 6.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Alopecia TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.25 [0.05, 1.30] | | < 1 | | 36% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | non important | - |
Arthralgia TRAE (grade 3-4) | 0.95 [0.19, 4.70] | | < 1 | | 0% | 4 studies (4/-) | 52.7 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.57 [0.15, 2.25] | | < 1 | | 0% | 4 studies (4/-) | 78.8 % | some concern | not evaluable | moderate | non important | - |
Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 0.38 [0.15, 0.93] | | < 1 | | 33% | 4 studies (4/-) | 98.3 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.71 [0.35, 1.44] | | < 1 | | 0% | 4 studies (4/-) | 82.8 % | some concern | not evaluable | moderate | non important | - |
Dry skin TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.35 [0.15, 0.82] | | < 1 | | 0% | 4 studies (4/-) | 99.2 % | some concern | not evaluable | moderate | non important | - |
Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 3.18 [0.85, 11.84] | | < 1 | | 0% | 4 studies (4/-) | 4.3 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.58 [0.13, 2.67] | | < 1 | | 0% | 4 studies (4/-) | 75.7 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.16 [0.18, 7.66] | | < 1 | | 0% | 4 studies (4/-) | 43.8 % | some concern | not evaluable | moderate | non important | - |
Increase AST TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.09 [0.22, 5.44] | | < 1 | | 0% | 4 studies (4/-) | 45.6 % | some concern | not evaluable | moderate | non important | - |
Myalgia TRAE (grade 3-4) | 0.94 [0.22, 4.02] | | < 1 | | 0% | 4 studies (4/-) | 53.2 % | some concern | not evaluable | moderate | non important | - |
Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 0.29 [0.07, 1.29] | | < 1 | | 0% | 4 studies (4/-) | 94.7 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.18 [0.04, 0.96] | | < 1 | | 0% | 4 studies (4/-) | 97.7 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.52 [0.32, 7.22] | | < 1 | | 0% | 4 studies (4/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
Pruritic rash TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
Uveitis TRAE (grade 3-4) | 1.17 [0.18, 7.68] | | < 1 | | 0% | 4 studies (4/-) | 43.7 % | some concern | not evaluable | moderate | non important | - |
Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.38 [0.10, 1.43] | | < 1 | | 0% | 4 studies (4/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |